An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples